Outcomes of Delays in Time to Treatment in Triple Negative Breast Cancer

Eastman, Amy; Tammaro, Yolanda; Moldrem, Amy; Andrews, Valerie; Huth, James; Euhus, David; Leitch, Marilyn; Rao, Roshni
June 2013
Annals of Surgical Oncology: An Oncology Journal for Surgeons;Jun2013, Vol. 20 Issue 6, p1880
Academic Journal
No abstract available.


Related Articles

  • Improved systemic therapy goal for triple-negative breast-cancer. Shafer, Emily // Hem/Onc Today;4/25/2011, Vol. 12 Issue 8, p16 

    The article discusses treatment options for triple-negative breast cancer.

  • Race did not affect outcome in triple receptor-negative breast cancer.  // Hem/Onc Today;10/10/2008, Vol. 9 Issue 18, p20 

    This article focuses on the statement issued by Shaheenah S. Dawood, a senior specialist registrar with Dubai Hospital in the United Arab Emirates, regarding the effect of race on outcome in triple receptor-negative breast cancer, at the 2008 Breast Cancer Symposium. According to the results of...

  • Triple-Negative Breast Cancer. Foulkes, William D.; Smith, Ian E.; Reis-Filho, Jorge S. // New England Journal of Medicine;11/11/2010, Vol. 363 Issue 20, p1938 

    The article discusses the occurrence of triple-negative breast cancer in women and the increase in its recognition by geneticists, pathologists, and oncologists in the U.S. in 2010. Basal-like breast cancer is related to triple-negative breast cancer. Triple-negative breast cancers are also...

  • Molecular Mechanism and Targeted Therapy Options of Triple-Negative (ER, PgR, HER-2/neu) Breast Cancer: Review. Kandula, Mahesh; Kumar Ch, Kalyan; Raju YS, Ammi // World Journal of Oncology;2013, Vol. 4 Issue 3, p137 

    Tripple negative breast cancer (TNBC) accounts for approximately 15% of breast cancers. It is defined by the absence of estrogen receptor (ER), progesterone receptor (PR), and HER-2 Over expression. Expression of ER, PR and HER-2 plays an important role in therapeutic assessment of patients with...

  • Breast Cancer Research: Blocking DNA: HDAC inhibitor targets triple negative breast cancer.  // Biomedical Market Newsletter;5/25/2012, Vol. 21, p1 

    The article offers information on the efficacy of histone de-acetylase inhibitor in treatment of triple negative breast cancer.

  • Surviving Triple Negative Breast Cancer: Hope, Treatment, and Recovery. Fox, Bettee-Lee // Library Journal;9/1/2012, Vol. 137 Issue 14, p121 

    A review of the book "Surviving Triple Negative Breast Cancer: Hope, Treatment, and Recovery," by Patricia Prijatel is presented.

  • 2014-82 Triple Negative Breast Cancer Day.  // Illinois Register;3/28/2014, Vol. 38 Issue 13, p7388 

    The article focuses on proclamations issued by Illinois governor Pat Quinn related to the Triple Negative Breast Cancer Day and Car Care Month as of March 2014. Topics discussed include the need of funding for developing a targeted treatment method for Triple Negative Breast Cancer, the need of...

  • Directed Therapy of Subtypes of Triple-Negative Breast Cancer. CAREY, LISA A. // Oncologist;Dec2010 Supplement, Vol. 15, p49 

    In developed countries, there has been a remarkable improvement in mortality from breast cancer, but almost all of that benefit has occurred in the estrogen receptor (ER)+ and human epidermal growth factor receptor (HER)-2+ subsets. Triple-negative breast cancer, defined as tumors that are...

  • Tolerability of Chemotherapy in HIV-Infected Women with Breast Cancer: Are There Prognostic Implications? Parameswaran, Lalitha; Taur, Ying; Shah, Monika K.; Traina, Tiffany A.; Seo, Susan K. // AIDS Patient Care & STDs;Jul2014, Vol. 28 Issue 7, p358 

    Breast cancer is the most commonly diagnosed malignancy in women, but little is known about therapeutic outcomes in patients with both breast cancer and HIV. We performed a retrospective cohort study of women with or without HIV undergoing treatment for breast cancer from 1996 to 2011. Cases...

  • San Antonio Breast Cancer Symposium.  // Medical Device Daily;12/14/2007, Vol. 11 Issue 227, p6 

    The article reports on a meeting held by the Triple Negative Breast Cancer Foundation and Susan G. Komen for the Cure in San Antonio, Texas. The meeting is dedicated to triple negative breast cancer. It is attended by several researchers from cancer institutions to discuss research collaboration...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics